Embecta (EMBC) 44th Annual J.P. Morgan Healthcare Conference summary

Business overview and performance

• Global leader in diabetes injection supplies, serving over 30 million users annually in more than 100 countries, producing approximately 8 billion units across three facilities.

• Achieved $1.1 billion in revenue last fiscal year, with an adjusted EBITDA margin of 38% and over $182 million in free cash flow.

• Pen needles and safety products contribute 85% of revenues and offset declines in syringes due to market shifts from vials to pens.

• Manufacturing expertise in high-volume plastics and automated assembly supports current and future product expansion.

• Revenue base is stable and recurring, withstanding external pressures like COVID-19 and changing diabetes treatment trends.

Strategic transformation and growth initiatives

• Transitioned from foundational setup post-spin to a growth-focused phase, aiming to become a broad-based medical supplies and drug delivery company.

• Brand transition from BD to embecta is underway, with 95% of U.S. and Canada revenue already converted; global completion targeted for 2026.

• Developing market-appropriate products for targeted regions, with launches expected in the near to midterm, focusing on markets where share is under 5%.

• GLP-1 B2B opportunities could drive over $100 million in revenue by 2033, with contracts in place and launches anticipated in Canada, Brazil, China, and India by 2026.

• Exploring B2B partnerships with pharma for drug delivery, expanding beyond injection devices.

Financial strategy and capital allocation

• Focused on debt reduction, reducing net leverage from nearly 4x to under 3x in fiscal 2025, with further reductions expected.

• Increasing financial flexibility to enable opportunistic M&A, targeting chronic care and drug delivery sectors.

• Margin improvement initiatives include evaluating market exits, optimizing go-to-market strategies, and introducing lower-cost products in select markets.

• Secured a 10-year cannula supply agreement to ensure raw material availability and cost management, with current contract running through 2032.

• Free cash flow for FY 2025 reached $182.4 million, supporting ongoing investments and flexibility.